

MiMedx Group, Inc. Announces Release Date for 2012 Fourth Quarter Results

February 7, 2013 11:19 AM ET

**PRESS RELEASE Contact: Michael Senken
Phone: (678) 384-6720**

MiMedx Group, Inc. Announces Release Date for 2012 Fourth Quarter Results

KENNESAW, Georgia, February 7, 2013 (PR Newswire) – MiMedx Group, Inc. (OTC: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today that its results for the fourth quarter ended December 31, 2012, will be released before the opening of the market on Thursday, March 7, 2013. MiMedx will host a live broadcast of its fourth quarter conference call on Thursday, March 7, 2013 at 10:30 AM EST. A listen-only simulcast of the MiMedx Group conference call will be available online at the Company's website at www.mimedx.com or at www.earnings.com. A 30-day online replay will be available approximately one hour following the conclusion of the live broadcast. The replay can also be found on the Company's website at www.mimedx.com or www.earnings.com.

About the Company

MiMedx[®] is an integrated developer, manufacturer and marketer of patent protected regenerative biomaterial products and bioimplants processed from human amniotic membrane. "Innovations in Regenerative Biomaterials" is the framework behind our mission to give physicians products and tissues to help the body heal itself. Our biomaterial platform technologies include the device technologies HydroFix[®] and CollaFix[™], and our tissue technologies, AmnioFix[®] and EpiFix[®]. Our tissue technologies are processed from human amniotic membrane that is derived from the donated placentas. Through our donor program, mothers delivering full-term Caesarean section births can elect in advance of delivery to donate the placenta in lieu of having it discarded as medical waste. We process the human amniotic membrane utilizing our proprietary Purion[®] Process, to produce a safe, effective and minimally manipulated implant for homologous use. MiMedx[®] is the leading supplier of amniotic tissue, having supplied over 120,000 implants to date to distributors and OEMs for application in the Wound care, Surgical, Sports Medicine, Ophthalmic and Dental sectors of healthcare.